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ABSTRACT
HARRISON, S. E., S. J. OLIVER, D. S. KASHI, A. T. CARSWELL, J. P. EDWARDS, L.M.WENTZ, R. ROBERTS, J. C. Y. TANG, R.M.
IZARD, S. JACKSON, D. ALLAN, L. E. RHODES, W. D. FRASER, J. P. GREEVES, AND N. P. WALSH. Influence of Vitamin D Sup-
plementation by Simulated Sunlight or Oral D3 on Respiratory Infection duringMilitary Training.Med. Sci. Sports Exerc., Vol. 53, No. 7,
pp. 1505–1516, 2021. Purpose: This study aimed to determine the relationship between vitamin D status and upper respiratory tract infection
(URTI) of physically active men and women across seasons (study 1) and then to investigate the effects on URTI and mucosal immunity of
achieving vitamin D sufficiency (25(OH)D ≥50 nmol·L−1) by a unique comparison of safe, simulated sunlight or oral D3 supplementation
in winter (study 2).Methods: In study 1, 1644military recruits were observed across basic military training. In study 2, a randomized controlled
trial, 250 men undertaking military training received placebo, simulated sunlight (1.3 standard erythemal dose, three times per week for 4 wk
and then once per week for 8 wk), or oral vitamin D3 (1000 IU·d
−1 for 4 wk and then 400 IU·d−1 for 8 wk). URTI was diagnosed by a physician
(study 1) and by using the Jackson common cold questionnaire (study 2). Serum 25(OH)D, salivary secretory immunoglobulin A (SIgA), and
cathelicidin were assessed by liquid chromatography–mass spectrometry LC-MS/MS and enzyme-linked immunosorbent assay. Results: In
study 1, only 21% of recruits were vitamin D sufficient during winter. Vitamin D–sufficient recruits were 40% less likely to suffer URTI than
recruits with 25(OH)D <50 nmol·L−1 (OR = 0.6, 95% confidence interval = 0.4–0.9), an association that remained after accounting for sex and
smoking. Each URTI caused, on average, three missed training days. In study 2, vitamin D supplementation strategies were similarly effective
to achieve vitamin D sufficiency in almost all (≥95%). Compared with placebo, vitamin D supplementation reduced the severity of peak URTI
symptoms by 15% and days with URTI by 36% (P < 0.05). These reductions were similar with both vitamin D strategies (P > 0.05). Supple-
mentation did not affect salivary secretory immunoglobulin A or cathelicidin. Conclusion: Vitamin D sufficiency reduced the URTI burden
during military training. Key Words: CHOLECALCIFEROL, 25-HYDROXYVITAMIN D, EXERCISE, UVB, IMMUNITY, VIRUS
Athletes and military personnel experience arduoustraining and nutritional inadequacy that may compro-mise host defense and increase their susceptibility to
respiratory illness such as the common cold, particularly dur-
ing the autumn-winter (1,2). The immunomodulatory effects
of vitamin D are considered to play a role in the seasonal stim-
ulus for upper respiratory tract infection (URTI) (3,4). This has
fueled considerable interest in potential prophylactic benefits
of vitamin D supplementation on URTI. Vitamin D can be ob-
tained from diet but is primarily synthesized by skin exposure
to sunlight ultraviolet B (UVB) radiation. As dietary vitamin
D intakes in the United States and Europe (112–330 IU·d−1
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[5–7]) are typically less than recommended (600 IU·d−1 [7,8]),
people who live at latitudes >35° or live indoors for the major-
ity of sunlight hours and cover-up from the sun are at higher
risk of vitamin D insufficiency. Indeed, epidemiological stud-
ies report vitamin D sufficiency (serum 25-hydroxyvitamin D
[25(OH)D] ≥50 nmol·L−1) in only 40%–65% of athletes and
military personnel during the winter, when skin exposure to
UVB radiation is negligible (9–11).
Vitamin D is widely accepted to influence both innate and
adaptive immunity with implications for host defense
(12,13). 25(OH)D is converted in the kidney to the biologi-
cally active form 1,25-dihydroxyvitamin D (1,25(OH)2D),
which enhances the innate immune response by the induction
of antimicrobial proteins like cathelicidin (13). Antimicrobial
proteins help to prevent URTI as part of the first line of de-
fense. The actions of vitamin D on adaptive immunity may
also be anti-inflammatory or “tolerogenic” (3). Immune toler-
ance has been described as the ability to dampen defense yet
control infection at a nondamaging level (14), prompting the
search for tolerogenic nutritional supplements to reduce URTI
burden (3). URTI burden can be assessed byURTI prevalence,
or the duration or severity of URTI. As such, maintaining or
achieving vitamin D sufficiency may reduce URTI burden
by preventing URTI symptoms but also by reducing the dura-
tion and/or severity of URTI (3,9,11).
Large cross-sectional and randomized placebo-controlled
supplementation studies in the general population highlight
that vitamin D reduces the burden of URTI (4,15,16). How-
ever, cross-sectional studies in young healthy and athletic pop-
ulations present conflicting findings (17–19), which might be
explained by small samples with few URTI, a limited range
of vitamin D concentrations due to single-season data collec-
tions, and a lack of control for factors known to independently
influence URTI (e.g., sex and smoking). Randomized con-
trolled trials investigating the effect of vitamin D supplemen-
tation on URTI and immunity in military recruits and
athletes are extremely limited and present a mixed picture
(20–23). These studies show reduced URTI symptoms (22),
improved mucosal immunity (i.e., salivary cathelicidin and
IgA) (21,23), and fewer missed training days due to URTI
(20), as well as no effect on URTI symptoms (20) or mucosal
immunity (22,23). The significant heterogeneity reported in
these trials may stem from variations in participant baseline vi-
tamin D status and dosing regimens; these factors are consid-
ered to modify the effect of vitamin D on immunity to
respiratory pathogens (15). The participants in these studies
were vitamin D sufficient at baseline (20,21), which likely lim-
ited the need and potential benefit of vitamin D supplementa-
tion (11). Also participants were administered higher oral
vitamin D doses than recommended by the Institute of Medi-
cine (IOM) and European Food Safety Authority (EFSA)
(21,22), increasing the risk of adverse outcomes (tolerable up-
per intake 4000 IU·d−1) (7,8). Although vitamin D is derived
from skin exposure to sunlight, the effect of safe skin sunlight
exposure on URTI burden and mucosal immunity has yet to
be studied. Ultraviolet radiation has a range of vitamin
D–dependent and vitamin D–independent effects on immu-
nity (24); however, whether there are additional benefits of
safe sunlight exposure, compared with oral vitamin D supple-
mentation, is unknown. Given the negative effect of URTI on
training and performance, it is important to determine whether
vitamin D supplementation has measurable and meaningful
effects on URTI in physically active populations (2,9,11).
First, the relationship between vitamin D status and URTI
prevalencewas determined in a large, prospective cohort study
of young men and women commencing military training
across all seasons (study 1). It was hypothesized that vitamin
D–sufficient recruits would be less likely to suffer URTI, com-
pared with those who had serum 25(OH)D <50 nmol·L−1.
Then, in a randomized placebo-controlled trial (study 2), the
effects on overall URTI burden (prevalence, duration, and sever-
ity) andmucosal immunity of achieving vitaminD sufficiency by
either simulated sunlight, following recommendations on safe,
low-level sunlight exposure (25), or oral D3 supplementation
in wintertime was investigated. Vitamin D sufficiency was
targeted because maintaining serum 25(OH)D concentration
≥50 nmol·L−1 has been recommended for health by the IOM
and EFSA and is achievable using safe doses of oral vitamin
D3 and simulated sunlight (7,8). It was hypothesized that
achieving vitamin D sufficiency during winter by vitamin D
supplementation would reduce URTI burden and improve
mucosal immunity compared with placebo supplementation.
METHODS
British Army recruits voluntarily participated in study 1 and
study 2 after providing fully informed written consent and
passing a clinician-screened medical assessment, which ex-
cludes a number of medical conditions, including chronic lung
diseases, and asthma symptoms or treatment in the last year.
Men (studies 1 and 2) were located at Infantry Training Centre
Catterick, UK (latitude 54°N), and women (study 1) were lo-
cated at Army Training Centre Pirbright, UK (latitude 51°N).
All volunteers were studied during 12 wk of basic military
training that follows a syllabus of basic military skills, includ-
ing physical training, weapon handling, map reading, and
fieldcraft. The progressive, structured, physical training program
included endurance training, circuit training, agility-based gym-
nasium work, assault course practice, and marching with a load.
The studies received ethical approval from the UK Ministry of
Defense Research Ethics Committee and were conducted in
accordancewith the Declaration of Helsinki (2013) (study reg-
istration references at www.clinicaltrials.org [NCT02416895,
NCT03132103]).
Study 1
Participants and study design. A total of 1644 men
andwomen (n= 1220men: 95%White ethnicity, age = 21± 3 yr;
body mass = 75.3 ± 9.9 kg, height = 1.77 ± 0.06 m, body mass
index [BMI] = 24.0 ± 2.7 kg·m−2, 38% smokers; n= 424women:
95%White ethnicity, age = 22 ± 3 yr, bodymass = 64.8 ± 8.2 kg,
height = 1.65 ± 0.06m, BMI = 23.7 ± 2.4 kg·m−2, 24% smokers)










participated in this prospective cohort study between January
2014 and September 2015. Participants were included if they
gave baseline blood samples, and URTI data were available
during the entire 12 wk of military training.
Experimental procedures.Baselinemeasures were col-
lected from each participant during the initial medical assess-
ment, including a venous blood sample for the determination
of serum 25(OH)D, height, bodymass, ethnicity, and smoking
history by self-reported questionnaire (Fig. 1). Medical records
were accessed to obtain physician-diagnosed URTI and lost
training days due to URTI. URTI was diagnosed by a single gen-
eral practice-trained physician. A lost training day was recorded
when a recruit was unavailable for normal military training.
Study 2
Participants and study design. A total of 250 men
(age = 22 ± 7 yr, body mass = 76.3 ± 10.8 kg,
height = 1.77 ± 0.06 m, BMI = 24.2 ± 3.0 kg·m−2) participated
in this double-blind, randomized placebo-controlled trial (Fig. 1).
Participants were recruited at the start of 12 wk of basic mil-
itary training during January and February of 2016 and
2017, when ambient UVB is negligible at UK latitudes
(50N–60°N) and serum 25(OH)D is at its annual nadir. Par-
ticipants were eligible to participate if they had sun-reactive
skin type of I to IV on the Fitzpatrick Skin Type Scale (26),
were not consuming supplements containing vitamin D, and
had not used a sunbed or traveled to a sunny climate in the
3 months before the study.
Experimental procedures. Participants were random-
ized within their platoons to one of four intervention groups:
1) oral vitamin D3 supplementation (ORAL), 2) oral placebo
supplementation (ORAL-P), 3) solar simulated radiation
(SSR), or 4) solar simulated radiation placebo (SSR-P). Block
randomization was used (www.randomiser.org) to achieve an
equal distribution of intervention groups within each platoon
so any differences in training conditions between platoons
did not influence the outcomes of the study. The intervention
strategy for the SSR and ORAL groups was to restore and
then maintain IOM- and EFSA-recommended vitamin D
sufficiency (serum 25(OH)D ≥50 nmol·L−1). Participants
completed a 4-wk restoration phase, necessary because serum
25(OH)D was at its annual wintertime nadir, followed by an
8-wk maintenance phase.
At baseline, during the routine initial medical assessment,
height and body mass were measured, a venous blood sample
was collected for the determination of serum 25(OH)D, and a
lifestyle questionnaire was completed to determine smoking
and alcohol use. Additional blood samples were obtained at
week 5 and week 12. At baseline, week 5, and week, 12 saliva
samples were collected in the evening, between 1800 and
2130 h, at least 15 min postprandial. Participants were ex-
cluded from analysis if they did not achieve ≥80% compliance
with the intervention. Compliance with the interventions was
FIGURE 1—A schematic of the prospective cohort study (study 1) that investigated the association between vitamin D status (serum 25(OH)D), URTI and
days lost from training, and the randomized controlled trial (study 2) that investigated the effects of vitamin D supplementation by solar simulated radiation
(SSR), oral vitamin D3 (ORAL), or placebo (SSR-P orORAL-P) onURTI andmucosal immunity. Blood samples were collected at baseline (studies 1 and 2),
week 5, and the end of week 12 (study 2). Saliva samples were collected at baseline, week 5, and the end of week 12 (study 2). The syringe icon represents the
blood sample; the head and the tube icon represent the saliva sample.







calculated from researcher weekly counts of oral capsules re-
maining in recruit pill boxes and SSR cabinet visit records. Vi-
tamin D from the diet was estimated in week 12 using a food
frequency questionnaire, and solar UVR exposure was mea-
sured in weeks 4 and 11 using polysulfone badges, worn on
the upper chest/anterior shoulder region on the outer clothes,
as described (10,27). The change in absorbance of the badges
due to exposure was measured using a spectrophotometer and
related to the erythemal effective UVR (sunburning) through a
standard polynomial relationship; data are expressed as stan-
dard erythemal dose (SED) per day (27). Participant dietary
vitamin D intake was calculated excluding the oral D3 supple-
ment participants received in the ORAL group. On completion
of the study, to confirm participant blinding, participants were
asked to guess the intervention they had received.
Simulated sunlight intervention. Simulated sunlight
was provided following guidelines on safe, low-level sunlight
exposure for vitamin D synthesis (6), described previously to
achieve serum 25(OH)D ≥50 nmol·L−1 in the majority of indi-
viduals with sun-reactive skin type of I to IV (28). Those
assigned to the SSR intervention were exposed three times a
week during the restoration phase and once per week during
the maintenance phase to an experimenter-controlled constant
UVR dose using a whole body irradiation cabinet (Hapro Jade,
Kapelle, The Netherlands) fitted with Arimed B fluorescent
tubes (Cosmedico, Stuttgart, Germany). The fluorescent tubes
emitted a UVR spectrum similar to sunlight (λ = 290–400 nm,
95% UVA = 320–400 nm, 5% UVB = 290–320 nm) that was
characterized by a spectroradiometer (USB2000+; Ocean Op-
tics BV, Duiven, The Netherlands) radiometrically calibrated
with traceability to UK national standards.
During each exposure, participants received a 1.3 SED
while wearing shorts and a T-shirt to expose ~40% skin sur-
face area. This dose is equivalent to ~15 min of midday sum-
mer sun exposure six times per week for a casually dressed
individual in northern England (latitude 53.5°N) (28). A con-
stant SSR dose was maintained during the study by monitor-
ing irradiance using a spectroradiometer (USB2000+, Ocean
Optics BV) and adjusting for any decrease in measured irradi-
ance emitted by increasing exposure time, as described (28)
(mean duration of SSR exposures was 222 ± 23 s). The expo-
sure time was controlled by using an electronic timer on the ir-
radiation cabinet. For the SSR-P participants, the number and
the duration of intervention exposures were the same as SSR,
except the irradiation cabinet fluorescent tubes were covered
with transparent UVR blocking film (DermaGard UV film;
SunGard, Woburn, MA). A spectroradiometer confirmed that
the UVR blocking film was effective at preventing transmis-
sion of 99.9% of UVR.
Oral vitamin D3. Participants receiving the ORAL inter-
vention consumed a vitamin D3 capsule daily, containing
1000 and 400 IU during the restoration and maintenance
phases, respectively (Pure Encapsulations, Sudbury, MA).
The restoration dose was based on previous predictive model-
ing to achieve serum 25(OH)D ≥50 nmol·L−1 (29) and pilot in-
vestigations that showed it achieved similar serum 25(OH)D
concentrations to SSR, and it was less than the tolerable upper
intake recommended by the IOM and EFSA (7,8). The ORAL
maintenance dose was shown in a pilot investigation to main-
tain serum 25(OH)D ≥50 nmol·L−1 and when accounting for
typical habitual dietary intake (5–7) was similar to IOM- and
EFSA-recommended dietary allowances (7,8). For 12 wk,
ORAL-P participants consumed an identical-looking cellulose
placebo capsule daily (Almac Group, County Armagh, UK).
Independent analysis found the vitamin D3 content of the
1000- and 400-IU capsules to be 1090 and 460 IU, respec-
tively, and confirmed the placebo did not contain vitamin D
(NSF International Laboratories, Ann Arbor, MI).
URTI diagnosis (study 2).As in study 1, medical records
were accessed to obtain data on physician-diagnosed URTI
and lost training days due to URTI. However, URTI was prin-
cipally monitored by self-reported daily symptoms recorded
using the Jackson common cold questionnaire (30). A strength
of the Jackson common cold questionnaire compared with
physician-diagnosed URTI is that URTI duration and severity,
as well as prevalence, can be assessed. Participants were asked
to rate eight symptoms (sneezing, headache, feeling generally
unwell, runny nose, blocked nose, sore throat, cough, and
chilliness) on a 4-point Likert scale (not at all = 0, mild = 1,
moderate = 2, severe = 3). Data were included when partici-
pants completed ≥80% of their daily Jackson questionnaires.
A URTI was defined by a daily total symptom score of ≥6
for two or more consecutive days (31). Further, the average
URTI duration (average duration of all URTI episodes), the
peak URTI symptom severity (maximumURTI severity score
on a single day of any URTI episode; maximum possible peak
severity is 24 arbitrary units [AU]), and the total number of
days with a URTI during basic military training for each par-
ticipant (total days with URTI; military training is 84 d in total)
were also determined. Self-reported URTI data were not re-
ported back to the military and therefore did not influence phy-
sician diagnosis of URTI or lost training days due to URTI.
Blood analysis (studies 1 and 2).Whole blood samples
were collected by venipuncture from an antecubital vein into
plain vacutainer tubes (Becton Dickinson, Oxford, UK) and left
to clot for 1 h. Subsequently, samples were centrifuged at
1500g for 10 min at 4°C, and the serum was aliquoted into
universal tubes before being immediately frozen at −80°C
for later analysis. Total serum 25(OH)D was measured with
high-pressure liquid chromatography–mass spectrometry.Analy-
ses were performed in a Vitamin D External Quality Assurance
Scheme–certified laboratory (Bioanalytical Facility, University
of East Anglia, Norwich, UK). The mean intra-assay coefficient
of variation for 25(OH)D3 and 25(OH)D2 was <10%, and the
lower limit of quantification was 0.1 nmol·L−1 (32).
Saliva collection and analysis (study 2). Saliva was
collected for 5 min in a preweighed 30-mL tube using the pas-
sive dribble method (33). Samples were weighed immediately
after collection, centrifuged at 1500g and 4°C for 10 min,
aliquoted, and then stored at −80°C. Samples were analyzed
in duplicate by enzyme-linked immunosorbent assay for secre-
tory immunoglobulin A (SIgA) and cathelicidin concentration










(Salimetrics, State Colelge, PA, and Hycult Biotech, Wayne, PA).
The mean intra-assay coefficient of variation was 2.3% for saliva
SIgA concentrations ranging from 0.02 to 0.51 mg·mL−1 and
10.2% for saliva cathelicidin concentrations ranging from
0.30 to 65.90 μg·L−1. Assuming the density to be 1.00 g·mL−1
for saliva, the secretion rate was calculated by multiplying
the saliva flow rate by concentration (33).
Statistical analysis. Statistical analyses were performed
using SPSS Version 25 (IBM Corp, New York, NY). Data
points that were more than three times the interquartile range
were deemed as outliers and removed. Where data were not
normally distributed, they were transformed using square-root
calculation. Significance was set at P < 0.05. For study 1, an es-
timated minimum required sample size of 1286 was calculated,
using a type 1 error (one-tailed) of 5%, a power of 80%, and an
anticipated odds ratio of 1.5 (equivalent to a small effect size)
and including a binomial variable at 20%. This was based on
previous literature describing the difference in URTI preva-
lence between individuals with low and high vitamin D status,
whereby 20% of individuals with high vitamin D status re-
ported a URTI (4), while also anticipating that 20% of indi-
viduals would have low vitamin D status across the whole
year (34). Logistic regression was used to compare vitamin
D status (25(OH)D ≥50 vs <50 nmol·L−1 and ≥75 vs <30,
≥50–<75, and <75 nmol·L−1) with URTI prevalence during
the 12-wk military training and the first 3 wk of military
training; circulating 25(OH)D has an estimated 3-wk half-
life (35,36). Sex and smoking were included as covariates
as they have previously been shown to influence URTI sus-
ceptibility (37,38). Chi-square tests were used to compare
URTI prevalence between vitamin D–sufficient participants
and those with serum 25(OH)D <50 nmol·L−1 and the propor-
tion of vitamin D–sufficient participants between seasons. We
used a one-way ANOVA to compare 25(OH)D between sea-
sons. For study 2, an estimated minimum required sample size
of 74 (37 in each comparison group) was calculated, using the
anticipated odds ratio of 0.3 for URTI prevalence between vi-
tamin D and placebo supplemented individuals with low vita-
min D status (15), and that 60% would self-report URTI
during basic military training (18,31,39), with a type 1 error
(one-tailed) of 5% and a power of 80%. URTI prevalence be-
tween vitamin D (SSR and ORAL) and placebo (SSR-P and
ORAL-P) supplementation groupswas compared by logistic re-
gression. Independent samples t-tests (two groups [SSR and
ORAL combined, SSR-P and ORAL-P combined]) were used
to compare vitamin D and placebo supplementation effects on
average URTI duration, total days with URTI, peak URTI se-
verity, saliva flow rate, SIgA, and cathelicidin. Serum 25(OH)
D, total days with URTI, URTI duration, URTI severity, saliva
flow rate, SIgA, and cathelicidin were compared between vita-
min D strategies and placebo groups by mixed-model ANOVA
(4 groups [SSR, ORAL, SSR-P, and ORAL-P] 3 time points
[baseline, week 5, andweek 12]). Sunlight exposure and dietary
vitamin D intake between SSR, ORAL, SSR-P, and ORAL-P
groups were compared by one-way ANOVA. Cohen’s d effect
sizes (d) are presented to indicate the meaningfulness of group
differences for total days with URTI, URTI duration, and URTI
severity, whereby values greater than 0.2, 0.5, and 0.8 represent
small, medium, and large effects, respectively (40).
RESULTS
Study 1
Low proportion of wintertime vitamin D sufficiency
in healthy young men and women. Baseline serum
25(OH)D concentration was lower in winter than all other sea-
sons (P < 0.01; Fig. 2A), when only 21% of participants were
vitamin D sufficient (baseline serum 25(OH)D ≥50 nmol·L−1;
Fig. 2B).
Vitamin D sufficiency associated with reduced
URTI prevalence.A total of 110URTI episodeswere recorded
with 7% of participants having at least one physician-diagnosed
FIGURE 2—Seasonal variation in serum 25(OH)D (A), vitamin D suffi-
ciency prevalence (serum 25(OH)D ≥50 nmol·L−1; B), and the URTI prev-
alence when serum 25(OH)D ≥50 nmol·L−1 or <50 nmol·L−1 (C) in 1644
men and women during 12 wk of military training. aLower than summer,
P < 0.05. bLower than autumn, P < 0.05. cLower than spring, P < 0.05.
*Lower than participants with serum 25(OH)D <50 nmol·L−1, P < 0.05.
Panel A data are presented asmean ± SD. Panels B and C are percentages
represented by vertical bars.







URTI. On average, each URTI resulted in 3.4 ± 3.3 lost train-
ing days (4% of total training days). Vitamin D–sufficient
participants at baseline were 40% less likely to have a
physician-diagnosed URTI, during 12 wk of training, than
participants with baseline serum 25(OH)D <50 nmol·L−1
(6% vs 9%, respectively, OR = 0.6, 95% confidence
interval = 0.4–0.9, P < 0.05; Fig. 2C). Vitamin D–sufficient
participants at baseline were half as likely to have a URTI
FIGURE 3—Flow diagram of the randomized controlled trial (study 2) investigating the effects of vitamin D supplementation on URTI and mucosal im-
munity. Flow diagram indicates the number of participants assessed, randomized to solar simulated radiation (SSR) or oral vitamin D3 (ORAL), or a pla-
cebo (solar simulated radiation placebo [SSR-P] or oral placebo [ORAL-P]), and statistically analyzed for URTI, salivary SIgA, and cathelicidin.










within the first 3 wk of training than participants with a base-
line serum 25(OH)D <50 nmol·L−1 (2% vs 5%, OR = 0.5,
95% confidence interval = 0.3–0.8, P < 0.05); approxi-
mately half of all URTI episodes occurred during this period
of training (47%, 52 URTI episodes). The association between
vitamin D status and URTI prevalence remained when con-
trolling for sex and smoking (P < 0.05). URTI prevalence
was not different between participants with a baseline serum
25(OH)D ≥75 nmol·L−1 and baseline serum 25(OH)D of <30,
≥50–<75, or <75 nmol·L−1 (P > 0.05).
Study 2
A flow diagram detailing the number of participants assessed,
recruited, and excluded from the analysis is provided in Figure 3.
There were no differences between treatment or control groups
in demographics, anthropometrics, or serum total 25(OH)D at
baseline (Table 1 and Fig. 4). During the 12-wk intervention,
daily sunlight exposure (0.35 ± 0.56 SED·d−1) and dietary vita-
min D were not different between groups (153 ± 136 IU·d−1,
P > 0.05). Participants were sufficiently blinded to the interven-
tion because only 38.4% correctly guessed their allocated
group, 27.3%were incorrect, and 34.3% said they did not know
whether they had received an active or placebo intervention.
Winter simulated sunlight and oral vitamin D3 in-
creased vitamin D sufficiency. At baseline, before win-
tertime vitamin D supplementation began, only one-quarter
(27%) of participants were vitamin D sufficient. Both SSR
and ORAL supplementation strategies were successful in
achieving vitamin D sufficiency in almost all by week 5
(≥95%). Week 5 and week 12 serum 25(OH)D concentrations
in the SSR and ORAL groups were higher than those in the re-
spective placebo groups (P < 0.001, Fig. 4).
Winter vitamin D supplementation reduced URTI
burden. A total of 93 Jackson-defined URTI episodes were
recorded with 69% of participants having at least one
self-reported URTI. The URTI prevalence was similar in vita-
min D and placebo supplementation groups for the restoration
(weeks 1–4), maintenance (weeks 5–12), and entire 12 wk pe-
riod of training (ORAL and SSR vs ORAL-P and SSR-P 57%
vs 63%, 29% vs 32%, and 71% vs 68%, respectively,
P > 0.05). The URTI average duration was also similar in vi-
tamin D and placebo supplementation groups (Fig. 5A,
P > 0.05). Winter vitamin D supplementation reduced URTI
burden compared with placebo, whereby participants had
15% lower peak URTI severity (P < 0.05; Fig. 5B), and
36% fewer total days with a URTI (P < 0.05; Fig. 5C).
Participants beginning vitamin D supplementation with serum
25(OH)D <50 nmol·L−1 had 33% shorter average URTI dura-
tion (P = 0.05; Fig. 5D), 21% lower peak URTI severity
(P < 0.05; Fig. 5E), and 43% fewer total days with URTI
(P < 0.05; Fig. 5F) when receiving vitamin D rather than pla-
cebo supplementation. There was no difference in URTI preva-
lence, duration, severity, or total days with URTI between
vitamin D supplementation strategies or between the different
placebo groups (P > 0.05). Specifically, the effect of ORAL
and SSR vitamin D supplementation strategies on URTI burden
was similar (ORAL vs SSR, URTI prevalence 70% vs 72%, to-
tal days with URTI 9.2 ± 8.4 vs 8.4 ± 6.7 d, URTI average du-
ration 6.9 ± 5.0 vs 6.5 ± 5.7 d, peak URTI severity 10.8 ± 3.0 vs
12.3 ± 3.8 AU, all P > 0.05). A physician-diagnosed URTI was
recorded for 8% of recruits, which was comparable with 8%
prevalence in the same seasonal period in study 1, and resulted
in 3.3 ± 1.3 training days lost.
Vitamin D supplementation and mucosal immu-
nity. Vitamin D supplementation and placebo groups did not
differ at baseline, and weeks 5 and 12, for saliva flow rate,
SIgA concentration, SIgA secretion rate, cathelicidin concen-
tration, and cathelicidin secretion rate (P > 0.05; Table 2).
DISCUSSION
The primary finding of these two studies was that vitamin D
sufficiency reduced the burden of URTI in healthy young
adults completing arduous military training. In study 1, vita-
min D–sufficient men and women were 40% less likely to suf-
fer a physician-diagnosed URTI during training than those
with serum 25(OH)D <50 nmol·L−1 (Fig. 2). Given this find-
ing, and that only 21% of participants were vitamin D suffi-
cient during winter, study 2 examined the effect of winter
vitamin D supplementation onURTI. Compared with placebo,
vitamin D supplementation reduced the severity of peak URTI
symptoms by 15% and days with URTI by 36% (Fig. 5).
Study 2 is the first to demonstrate the benefits of vitamin D
supplementation, in line with IOM and EFSA guidelines, on
URTI in an active population. These findings are timely as
TABLE 1. Study 2 baseline participant demographics, anthropometrics, and lifestyle behaviors in solar simulated radiation (SSR), SSR placebo (SSR-P), Oral vitamin D3 (ORAL), and oral
placebo (ORAL-P) supplemented groups.
SSR (n = 63) SSR-P (n = 59) ORAL (n = 63) ORAL-P (n = 65)
Demographics
Age (yr) 21 ± 3 22 ± 3 21 ± 3 23 ± 12
Ethnicity (White Caucasian), n (%) 61 (98) 57 (97) 63 (100) 65 (100)
Skin type (I, II, III, IV), n (%) 4 (7), 16 (26), 33 (53), 9 (15) 4 (7), 16 (27), 28 (48), 11 (19) 5 (8), 18 (29), 33 (52), 7 (11) 3 (5), 19 (29), 29 (45), 14 (22)
Anthropometrics
Height (m) 1.78 ± 0.06 1.78 ± 0.06 1.77 ± 0.07 1.78 ± 0.06
Body mass (kg) 76 ± 11 77 ± 11 75 ± 11 77 ± 10
BMI (kg·m−2) 24 ± 3 24 ± 3 24 ± 3 24 ± 3
Lifestyle behaviors
Alcohol user, n (%) 51 (82) 47 (80) 55 (87) 51 (78)
Smoker, n (%) 23 (37) 25 (42) 26 (41) 21 (32)
Data are presented as mean ± SD unless otherwise stated. There were no differences in demographics, anthropometrics, or lifestyle behaviors between groups (P > 0.05).







the nutrition and athletic performance position stands from the
International Olympic Committee and American College of
Sports Medicine highlight that vitamin D insufficiency is
widespread in athletes (9,41).
In study 1, vitamin D–sufficient men and women were less
likely to suffer a physician-diagnosed URTI during training
than those with serum 25(OH)D of <50 nmol·L−1 (Fig. 2).
This finding can be considered robust as it was observed after
accounting for sex and smoking, which is a strength of this
study when compared with previous research that has not con-
trolled for factors known to independently influence URTI
(17–19). In study 1, the association between baseline vitamin
D status and URTI was stronger during the first 3 wk of the
12-wk training program, which might be expected given the
high incidence of URTI at this time, and that 25(OH)D has ap-
proximately a 3-wk half-life (35,36). Study 1 extends our un-
derstanding of the relationship between vitamin D and URTI
in active populations as data were collected in a large sample,
across all seasons, and with a large range of serum 25(OH)D
concentrations. The burden of URTI was evident as each
URTI resulted in an average of 3 d missed training.
In study 2, vitamin D supplementation by simulated sun-
light and oral vitamin D3 was similarly effective to achieve
IOM- and EFSA-recommended vitamin D sufficiency in the
majority of individuals (≥95%; Fig. 4). Vitamin D supplementa-
tion did not reduce self-reported URTI prevalence or benefit
mucosal immunity compared with placebo (Table 2). How-
ever, vitamin D supplementation reduced URTI burden com-
pared with placebo: participants receiving vitamin D reported
15% lower peak URTI severity and 36% fewer days with URTI
compared with placebo (Fig. 5). The magnitude of the reduc-
tion in URTI burden in study 2 can be considered meaningful
as effect sizes were medium to large. These findings also
broadly agree with the previous research in this area (20,22),
i.e., vitamin D supplementation reduced URTI symptoms
(22) and absence from duty due to respiratory infection (20).
The different methods used to assess URTI in the studies
may explain the difference between study 1 and study 2 prev-
alence findings. The lower URTI prevalence in study 1 than
study 2 (7% vs 69%) indicates that physician diagnosis of
URTI compared with daily self-report likely missed more minor
illnesses that did not warrant a medical visit. Further, study 2
physician-diagnosed URTI prevalence was 8%, which was the
same as study 1, when controlling for season. Self-reportedURTI
data were not reported back to the military and therefore did not
influence physician diagnosis of URTI or lost training days due
to URTI. When considered carefully in the context of these
different methods, the findings of studies 1 and 2 are comple-
mentary. In study 2, lower peak URTI severity and fewer days
with URTI with vitamin D supplementation, compared with
placebo, would be expected to translate to vitamin D–
sufficient individuals reporting less to medical services, and
consequently having fewer physician-diagnosed URTI than
those individuals with 25(OH)D <50 nmol·L−1. This is en-
tirely consistent with the main finding of study 1: URTI prev-
alence was lower in vitamin D–sufficient individuals than
those with 25(OH)D <50 nmol·L−1 (Fig. 2).
Study 2 findings are notable as they highlight that vitamin D
supplementation may reduce URTI burden rather than prevent
URTI. Vitamin D supplementation did not influence the innate
mucosal antimicrobial proteins SIgA and cathelicidin that form
an important part of the first line of defense against URTI.
Based on these findings, it is speculated that the tolerogenic
FIGURE 4—Serum 25(OH)D in men completing military training while
receiving 12 wk of vitamin D supplementation (solar simulated radiation
[SSR] or oral vitamin D3 [ORAL]) or a placebo (solar simulated radiation
placebo [SSR-P] or oral placebo [ORAL-P]). Combined vitamin D inter-
ventions (SSR and ORAL) vs combined placebo (SSR-P and ORAL-P;
A), ORAL vs ORAL-P (B), and SSR vs SSR-P (C). *Greater than placebo,
P < 0.05. †Greater than baseline, P < 0.05. ‡Greater than week 5, P < 0.05.
Data are presented as mean ± SD.










effects of vitamin D may reduce URTI burden by limiting in-
flammation in response to an infection (i.e., controlling infection
at a nondamaging level) (3,14,42), which subsequently leads to a
reduction in self-reported URTI severity and duration (14). Fu-
ture research is warranted to investigate the effect of vitamin D
supplementation on URTI and circulating anti-inflammatory
cytokines (3). To better understand the influence of vitamin
D supplementation on the immune pathway, these studies
should examine serum 1,25(OH)2D, the biologically active
form, as well as 25(OH)D. It is also worth noting that women
FIGURE 5—URTI average duration (A and D), peak URTI severity (B and E), and total days with URTI during military training (C and F), in the vitamin
D supplementation (SSR andORAL) vs placebo supplementation groups (SSR-P andORAL-P) in all participants (left-hand column) and participants with
a baseline 25(OH)D <50 nmol·L−1 (n = 62; right-hand column). * and # lower than placebo, P < 0.05 and P = 0.05, respectively. Data are presented as
mean ± SD. d = Cohen’s d effect size. aMaximum possible peak severity (24 AU). bTotal number of days for military training (84 d).







were not included in study 2, and therefore future work should
determine the influence of vitamin D supplementation on
URTI burden in women.
The pathological determination of URTI using nasopharyn-
geal throat swabs would have provided assurance that the
URTI reported in studies 1 and 2 was infection by origin rather
than due to some other cause, e.g., allergy. Nonetheless, previ-
ous research has shown that infectious pathogens of URTI
identified by self-reported questionnaire methods were con-
firmed in 82% of recreationally active men and women (31)
and in 75% of Winter Olympic Games athletes (43). Further-
more, study 2 was completed during winter when common
cold and flu are prevalent and symptoms caused by summer al-
lergies are rare. Rejecting self-reported URTI for pathogen
recognition is not advocated; rather, future research is advised
to use a blended approach incorporating the infectious etiol-
ogy with real-world URTI symptomology. Study 2 findings
highlight the importance of the daily assessment of URTI
symptoms to monitor URTI duration and severity as well as
prevalence, regardless of whether pathogen recognition is
available. The assessment of URTI duration and severity will
be important in future studies wishing to further examine po-
tential tolerogenic effects of vitamin D on immune health. Fu-
ture research should also adopt the blended approach to more
fully understand the effectiveness of other potential treatments
for URTI.
Currently, there is no consensus for the optimal vitamin D
threshold or dose for immune health (13). Participants begin-
ning supplementation with serum 25(OH)D <50 nmol·L−1 re-
ported shorter URTI duration when receiving vitamin D
compared with placebo supplementation. Further evidence
that participants with serum 25(OH)D <50 nmol·L−1 benefitted
more from vitamin D supplementation than the entire sample is
clear when examining the effect sizes between vitamin D and
placebo for URTI outcomes: small–medium effect sizes for
the entire sample, compared with medium and large effect sizes
for participants with serum 25(OH)D <50 nmol·L−1 (Fig. 5).
Compared with the IOM- and the EFSA-recommended vitamin
D sufficiency, no additional protection from URTI of higher
vitamin D status, including a previously proposed optimal
threshold (serum 25(OH)D > 75 nmol·L−1) (44), was revealed.
These findings alongside other findings from this research pro-
gram that show benefits of vitamin D sufficiency on in vivo im-
munity (45) support 25(OH)D ≥50 nmol·L−1 for immune
health. Further, the current studies highlight that exercise per-
formance may indirectly benefit from maintaining vitamin D
sufficiency by reducing lost training days to URTI.
No additional benefit of SSR compared with oral vitamin
D3 supplementation was shown on URTI, immune function
(this study and [45]), or exercise performance (10). Conse-
quently, active people are advised to take the 400-IU·d−1 oral
vitamin D3 dose, from the maintenance phase of study 2, to
maintain vitamin D sufficiency when exposure to ambient
UVB is inadequate: between early autumn and late winter,
and for those that live and/or exercise indoors for the majority
of sunlight hours or cover-up from the sun. When accounting
for typical dietary vitamin D intake, this oral vitamin D3 sup-
plementation approach corresponds with current IOM and
EFSA recommendations (600 IU·d−1) for bone and general
health, and unlike simulated sunlight, there is no time burden
for an individual, no requirement for bulky irradiation cabi-
nets, and oral vitamin D3 supplementation is effective regard-
less of sun-reactive skin type. Nevertheless, low-level sunlight
may provide benefits to human health, additional to vitamin D
synthesis, and this remains an area of active research (24).
CONCLUSIONS
Vitamin D sufficiency reduced URTI burden in military re-
cruits during arduous training. In study 1, vitamin D–sufficient
recruits were less likely to have a URTI compared with those
with serum 25(OH)D <50 nmol·L−1. In study 2, winter vita-
min D supplementation, which achieved vitamin D sufficiency
in almost all (≥95%), reduced peak URTI severity and total
days with URTI compared with placebo. To reduce the burden
of URTI, maintaining vitamin D sufficiency is recommended
for military personnel and other active populations, such as
athletes who participate in arduous training.
TABLE 2. Influence of 12 wk solar simulated radiation (SSR), placebo solar simulated radiation (SSR-P), Oral vitamin D3 (ORAL), and oral placebo (ORAL-P) on saliva flow rate (FR), SIgA
concentration, SIgA secretion rate (SR), cathelicidin concentration, and cathelicidin SR.
SSR SSR-P ORAL ORAL-P
FR (μL·min−1) Baseline 205 ± 128 184 ± 181 260 ± 214 241 ± 173
ΔBaseline to week 5 +5 ± 124 +26 ± 160 −36 ± 159 −5 ± 208
ΔBaseline to week 12*,** +69 ± 125 +124 ± 207 +24 ± 243 +64 ± 201
SIgA concentration (mg·mL−1) Baseline 0.14 ± 0.08 0.12 ± 0.06 0.13 ± 0.06 0.12 ± 0.05
ΔBaseline to week 5* +0.01 ± 0.08 +0.04 ± 0.09 +0.02 ± 0.09 +0.02 ± 0.07
ΔBaseline to week 12* +0.00 ± 0.05 +0.03 ± 0.06 +0.03 ± 0.1 +0.03 ± 0.09
SIgA SR (μg·min−1) Baseline 27 ± 17 18 ± 11 26 ± 19 25 ± 17
ΔBaseline to week 5 −2 ± 22 +12 ± 16 +1 ± 18 +1 ± 20
ΔBaseline to week 12*,** +9 ± 16 +25 ± 31 +10 ± 22 +14 ± 24
Cathelicidin concentration (μg·L−1) Baseline 14 ± 11 14 ± 14 13 ± 13 12 ± 11
ΔBaseline to week 5 −8 ± 16 +6 ± 18 −2 ± 10 −1 ± 15
ΔBaseline to week 12 −5 ± 14 +1 ± 19 −4 ± 16 −1 ± 17
Cathelicidin SR (ng·min−1) Baseline 3.25 ± 3.04 1.69 ± 1.91 2.42 ± 2.28 3.13 ± 4.79
ΔBaseline to week 5 −0.82 ± 3.82 +0.96 ± 1.81 −0.54 ± 1.78 −1.35 ± 4.25
ΔBaseline to week 12 −0.70 ± 4.10 +2.15 ± 3.61 +0.14 ± 2.45 −0.64 ± 5.60
Data are presented as mean ± SD.
*Main effect of time vs baseline, P < 0.05.
**Main effect of time vs week 5, P < 0.05.
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